Dr Subir Biswas

CHIEF BUSINESS DEVELOPMENT OFFICER

Dr. Subir Biswas's journey in the biopharma industry is a testament to his unwavering dedication and expertise in process development. After completing his post-doctoral studies at the prestigious University of North Carolina, USA, Dr. Subir returned to his homeland, India, armed with a wealth of knowledge and experience.

With 15 years of experience in the biopharma industry, Dr. Subir has established himself as a seasoned technocrat, renowned for his contributions to the development of biologics and biosimilars. His expertise spans a wide range of areas, including cell line development, antibody discovery, and engineering.

One of Dr. Subir's most notable achievements is his role in the development of biosimilars such as Trastuzumab, Bevacizumab, Rituximab, and Etanercept. These groundbreaking therapies have revolutionized treatment options for patients around the world, offering hope and improved outcomes.

Based in Hyderabad, Dr. Subir has played a pivotal role in driving business growth and expansion in the Indian market. With his keen business acumen and strategic vision, he has developed a business worth approximately 9 million USD, solidifying his reputation as a trusted leader in the industry.

But beyond his professional accomplishments, Dr. Subir remains committed to making a difference in the lives of patients. His relentless pursuit of excellence and innovation continues to drive him forward, as he seeks to push the boundaries of what is possible in biopharma research and development.

As Dr. Subir looks to the future, he remains focused on his mission to improve healthcare outcomes and advance medical science. With his expertise, passion, and unwavering determination, Dr. Subir Biswas is poised to continue making meaningful contributions to the biopharma industry for years to come.